NOV 0 6 2008

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Application Number		10584438
Filing Date		
First Named Inventor	M. Kr	oz
Art Unit		
Examiner Name		
Attorney Docket Number		P31755 USA

		<u> </u>			.PATENTS	
Examiner nitial*	miner Cite No Patent Numbe		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	4736866		1988-04-12	Leder and Steward	
	2	4857467		1989-08-14	Kotikanyadan and Motohiro	
	3	5489743		1996-02-06	Robinson, et al	
	4	5576195		1998-11-19	Robinson, et al.	
	5	5637504		1997-06-10	Hinchliffe and Chinery	
	6	5641670		1997-06-24	Treco, et al	
	7	5846818		1998-12-08	Robinson, et al.	
	8	6540993		2003-04-01	Warne, et al.	

Application Number		10584438
Filing Date		
First Named Inventor M. Kro		oz
Art Unit		
Examiner Name		
Attorney Docket Number		P31755 USA

	, -		U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Publication Code <sup>1</sup> Date		ation	Name of Pat of cited Docu	entee or Applicant ument	Rele	es,Columns,Lines where vant Passages or Relev res Appear	
	1	20030125247		2003-07	7-03	Rosen and Ha	aseltine			
	2	20030221201		2003-1	1-27	Prior, et al				•
	3	20040023334		2004-02	2-05	Prior, Christop	oher D.			
If you wis	h to a	dd additional U.S. Publ	ished Ap					d butto	on.	
	1			FOREI	GN PAT	TENT DOCUM	MENTS			·
Examiner Initial*	Cite No	Foreign Document Number³	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patented Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	EP201239	EP			1986-11-12	Hinchliffe and Kenr	ıy		
	2	EP322094	EP			1989-06-28	Geisow, et al			
	3	WO8704462	wo			1987-07-30	Wilson, et al			
	4	WO9001063	wo	. <u>.</u> .		1990-02-08	Goodey, et al			
	5	WO9106657	wo			1991-05-16	Bebbington & Yarra	inton		

Application Number		10584438
Filing Date		
First Named Inventor	M. Kr	roz
Art Unit		
Examiner Name		
Attorney Docket Number		P31755 USA

		-			
6	WO9523857	wo	1995-09-08	Gilbert and Kerry-Williams	
7	WO9533833	wo	1995-12-14	Quirk and Wood	
8	WO9629411	wo	1996-09-26	Treco, et al	
9	WO9724445	wo	1997-07-10	Ballance, David James	
10	WO0044772	wo	2000-08-03	van Urk, et al	
11	WO0177137	wo	2001-01-18	Rosen and Haseltine	
12	WO0179443	wo	2001-10-25	Rosen and Haseltine	
13	WO0179444	wo	2001-10-25	Rosen and Haseltine	
14	WO0179480	wo	2001-10-25	Haseltine and Rosen	
15	WO03030821	wo	2003-04-17	Rosen and Haseltine	
16	WO03059934	wo	2003-07-24	Rosen and Haseltine	

Application Number		10584438
Filing Date		
First Named Inventor	M. Kr	oz
Art Unit		
Examiner Name		
Attorney Docket Number		P31755 USA

	17	WO03060071	wo		2003-07-24	Ballance, et al					
	18	WO03066824	wo		2003-08-14	Hauser, et al					
If you wis	h to a	dd additional Foreign P	atent Document	citation	information p	lease click the Add butt	on	1			
			NON-PATE	NT LITE	RATURE DO	CUMENTS					
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approdate, pages(s), volume	priate), title of the item issue number(s),	T5			
	1	BEBBINGTON, et al., High-Level Expression of a Recombinant Antibody From Myeloma Cells Using A Glutamine Synthetase Gene As An Amplifiable Selectable Marker, Bio/Technology, February 1992, pp.169-175, Vol. 10, 1992 Nature Publishing Group.									
	2	CLELAND, et al., The Development of Stable Protein Formulations: A Close Look at Protein aggregation, Deamidation, and Oxidation, Critical Reviews in Therap0eutic Drug Carrier Systems, 1993, pp. 307-377, Vol. 10, CRC Press, IncA									
	3	CZUPRYN, et al., Alanine-Scanning Mutagenesis of Human Interleukin-11: Identification of Regions Important for Biological Activity, Annals New York Academy of Sciences, 1995, pp. 152-164, Vol. 762, Supplied by The British Library - "The world's knowledge".									
	4	DESANTIS, et al., Chemical Modification of Enzymes for Enhanced Functionality, Current Opinions in Biotechnology, 1999, pp. 324-330, Vol. 10, Supplied by The British Library - "The world's knowledge".									
	5	DOBELI, et al., Role of the Carboxy-Terminal Sequence on the Biological Activity of Human Immune Interferon (IFN-y), Journal of Biotechnology, 1988, pp. 199-216, Vol. 7, Elsevier Science Publishers D.V.									
	6	HUANG, et al., [Purificat Pastoris], Sheng Wu Go	HUANG, et al., [Purification and Characterization of Recombinant Human Interleukin 11 Which Expressed by Pichia Pastoris], Sheng Wu Gong Cheng Xue Bao, 2001, pp: 250-253, Vol. 17(3) (Abstract), NCBI PubMed, U.S.A.								
	7	GAYLE, et al., Identifica October 15, 1993, pp. 22 Inc., U.S.A.	tion of Regions in 2105-22111, Vol. 2	Interleuk 268, No.	kin-1a Important 29,The America	for Activity, The Journal of Society for Biochemistr	of Biological Chemistry, ry and Molecular Viology,				

Application Number		10584438
Filing Date		
First Named Inventor	M. Kro	oz
Art Unit		
Examiner Name		
Attorney Docket Number		P31755 USA

8	HOFFMAN and WINSTON, Isolation and Characterization of Mutants Constitutive for Expression of the fbp1 Gene of Schizosaccharomyces pombe, Genetics, April 1990, pp: 807-816, Vol. 124, The Genetics Society of America, U.S.A.								
9	MAUNDRELL, KINSEY, nmt1 of Fission Yeast, A Highly Transcribed Gene Completely Repressed by Thiamine, The Journal of Biological Chemistry, July 5, 1990, pp. 10857-10864, Vol. 265, No. 19, The American Society for Biochemistry and Molecular Biology, Inc. U.S.A.								
10	PLANZ, et al., A Fusion Protein of Interleukin-11 and Soluble Interleukin-11 Receptor Acts As A Superagonist on Cells Expressing gp103, FEBS Letters, 450, 1999, pp. 117-122, Federation of European Biochemical Societies.								
11	RON, et al., Expression of Biologically Active Recombinant Keratinocyte Growth Factor, The Journal of Biological Chemistry, 1993, pp. 2984-2988, Vol. 268, No. 4, Issue of February 5, 1993, U.S.A.								
12	SLEEP, et al., Saccharomyces Cerevisiae Strains That Overexpress Heterologous Proteins, Bio/Technology, February 1991, pp. 183-187, Vol. 9, Delta Biotechnology Limited, Great Britain.								
13	UCHIDA, et al., Pharmacokinetics of [125I]-recombinant Human Interleukin-11, European Journal of Drug Metabolism and Pharmacokinetics, 1998, pp. 403-410, Vol. 23, No. 3, Supplied by The British Library - "The world's knowledge".								
14	WANG, et al., Expression of the Recombinant Human Interleukin-11 in Pichia Pastoris, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2001, pp: 659-664, Vol. 33(6), (Abstract), NCBI PubMed, U.S.A.								
15	ZHU, et al., [Expression and Purification of Recombinant Human Interleukin-11 in Pichia Pastoris], Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2001, pp. 127-31, Vol. 23(2), (Abstract), NCBI Pub Med, U.S.A.								
If you wish to	add additional non-patent literature document citation information please click the Add button								
	EXAMINER SIGNATURE								
Examiner Sign	nature Date Considered								
*EXAMINER: citation if not i	Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a n conformance and not considered. Include copy of this form with next communication to applicant.								
Standard ST.3).  4 Kind of docume	of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIF) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent docunt by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark I translation is attached.	iment							